interferon alfa
1 product
8 abstracts
Abstract
Phase 3 study of the lysine-specific demethylase 1 (LSD1) inhibitor bomedemstat in patients with essential thrombocythemia (ET).Org: Sheba Medical Center–Tel HaShomer, Tel Aviv-Yafo, Royal Adelaide Hospital and SA Pathology,
Abstract
PD-1 inhibitors versus conventional therapies for adjuvant treatment of resected acral melanoma: A systematic review and meta-analysis.Org: Fudan University Shanghai Cancer Center, Shanghai Medical College, Fudan University, Fudan University (Xiamen Branch), Department of Musculoskeletal Oncology, the First Affiliated Hospital of Sun Yat-Sen University, Guangzhou, China, Department of Oncology and Haematology, Division of Oncology, University Hospital of Modena, Modena, Italy,
Abstract
Longitudinal assessment of cardiac involvement in Erdheim-Chester disease using cardiac magnetic resonance imaging.Org: Hôpital Pitié-Salpêtrière, Service de Médecine Interne 2, Hôpital Pitié Salpêtrière, Assistance Publique Hôpitaux de Paris (AP-HP), Department of Internal Medicine C, University Hospital Greifswald, Greifswald, Germany,
Abstract
Ex-vivo analysis of programmed cell death on fibrolamellar carcinoma.Org: Rush University Medical School, FibroFighters Foundation, Nagourney Cancer Institute, FibroFighters.org, Rush University Medical Center,
Abstract
Subsets of interferon signaling and response to immune checkpoint blockade.Org: Yale School of Medicine, University of Southern California Marshall School of Business, Yale University School of Public Health,
Abstract
Augmented curation of disease diagnoses and medications for patients with hepatocellular carcinoma.Org: nference, nference Labs,
Abstract
Influence of follow-up time on outcome of children and adolescents with atypical Spitz tumor/Spitz melanoma (AST/SM): Results from the MACMEL registry.Org: St Jude Childrens Research Hospital, St. Jude Children's Research Hospital, Department of Oncology, St. Jude Children's Research Hospital,
Abstract
Impact of adjuvant immunotherapy in resected stage II/III/IV melanoma: A single center experience.Org: Vall d'Hebron University Hospital and Institute of Oncology (VHIO), Barcelona, Spain, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, SOLTI Cancer Research Group, Hospital Vall d'Hebron,